Selcuk University, Faculty of Medicine, Department of Radiation Oncology, Konya, Turkey.
Selcuk University, Faculty of Medicine, Department of Medical Oncology, Konya, Turkey.
Transpl Immunol. 2021 Dec;69:101489. doi: 10.1016/j.trim.2021.101489. Epub 2021 Oct 20.
This study aimed to compare preoperative chemoradiotherapy (CRT) with postoperative CRT regarding survival, local control, disease control, sphincter preservation, toxicity and also prognostic factors for the treatment of locally advanced rectal cancer.
Records of 140 patients with locally advanced rectal cancer who received preoperative or postoperative CRT were analyzed retrospectively. We compared the treatment groups (preoperative vs postoperative) according to baseline characteristics (demographic and rectal cancer disease characteristics), and also carried out the survival analyses.
From January 2010 to December 2019, 140 patients were included in the analysis, 65 received preoperative treatment and 75 postoperative treatment. There was no difference in survival, recurrence or distant metastasis rate in both treatment groups. The ratios of the failure to complete adjuvant chemotherapy (32% vs 4.6%) and acute grade 3-4 toxicity (32% vs 6.2%) were higher in the postoperative group (p < 0.001). In lower located tumors (≤5 cm from anal verge) the ratio of the sphincter preserving in the preoperative group was 60.7% (n = 17/28), and was 16.6% (n = 3/18) in the postoperative group (Yates χ2 = 5.829, p = 0.005).
This study showed no difference in recurrence and survival rate. Preoperative CRT is the preferred treatment for patients with locally advanced rectal cancer, given that it is associated with a superior overall treatment compliance rate, reduced toxicity, and an increased rate of sphincter preservation in low-lying tumors, but not for overall survival.
本研究旨在比较术前放化疗(CRT)与术后 CRT 在生存、局部控制、疾病控制、保肛率、毒性方面的差异,并分析治疗局部进展期直肠癌的预后因素。
回顾性分析了 140 例接受术前或术后 CRT 的局部进展期直肠癌患者的病历资料。我们根据基线特征(人口统计学和直肠癌疾病特征)比较了治疗组(术前 vs 术后),并进行了生存分析。
2010 年 1 月至 2019 年 12 月,共纳入 140 例患者,其中 65 例接受术前治疗,75 例接受术后治疗。两组患者的生存、复发或远处转移率均无差异。术后组辅助化疗完成率(32% vs 4.6%)和急性 3-4 级毒性发生率(32% vs 6.2%)较高(p<0.001)。低位肿瘤(距肛缘≤5cm)患者中,术前组保肛率为 60.7%(n=28/46),术后组为 16.6%(n=3/18)(Yates χ2=5.829,p=0.005)。
本研究显示两组患者的复发率和生存率无差异。术前 CRT 是局部进展期直肠癌患者的首选治疗方法,因为它与更高的整体治疗依从性、更低的毒性和低位肿瘤保肛率的增加相关,但与总体生存率无关。